Study of Dual Trigger Ovulation in Oocyte Donors (DUALTRIGGER)
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Randomized Prospective Trial of Dual Trigger Ovulation in Oocyte Donors|
- Number of Subjects Having Adverse Events [ Time Frame: 1 month ] [ Designated as safety issue: Yes ]Any donor having a serious complication such as severe hyperstimulation syndrome, ovarian torsion, infection or peritoneal bleeding will be recorded
- Number of days post retrieval until subject is able to resume her usual activities [ Time Frame: 7 days post retrieval ] [ Designated as safety issue: Yes ]Subjects will complete a brief questionnaire on post retrieval day 7. They will state how many days after retrieval they were able to resume their usual activities.
- Ovarian Volume [ Time Frame: 7 days post retrieval ] [ Designated as safety issue: Yes ]Ovarian volume of both ovaries will be measured by ultrasound on post op day number 7. Measurements will be taken in three different dimensions and volume calculated from those measurements.
- Number of mature oocytes retrieved [ Time Frame: 1 day post ovulation ] [ Designated as safety issue: No ]Number of mature oocytes retrieved will assess the efficacy of the intervention
- Pregnancies per Transfer [ Time Frame: 4 weeks post retrieval ] [ Designated as safety issue: No ]Pregnancy rate per transfer will be assessed by hCG level on day 14 post retrieval and clinical pregnancy rate will be assessed by ultrasound on day 28 post retrieval. This will additionally assess efficacy of intervention.
|Study Start Date:||January 2013|
|Estimated Study Completion Date:||June 2017|
|Estimated Primary Completion Date:||June 2016 (Final data collection date for primary outcome measure)|
Active Comparator: hCG
standard dose of hCG for ovulation trigger
Active Comparator: Lupron Trigger
Leuprolide acetate 2 mg ovulation trigger
Drug: Lupron Trigger
leuprolide acetate 2 mg SQ
Experimental: Dual Trigger
Lupron and hCG combined ovulation trigger
Drug: Dual Trigger
a combination of the two drugs in low dosage (leuprolide acetate 2 mg and hCG 1500 IU).
The study population will consist of young women, age 21 to 34, presenting to our facility with the desire to donate oocytes and who meet FDA and program requirements for donation.
Participants will be randomized to one of the three treatment interventions for triggering ovulation: 1) a standard dose of hCG, 2) leuprolide acetate 2 mg alone, or 3) a combination of the two drugs in low dosage (leuprolide acetate 2 mg and hCG 1500 IU).
Study participants who choose to repeat oocyte donation during the course of the study trial, and who consent to participate in the trial again, will be randomized in a cross-over manner for any subsequent trials.
Following randomization, the clinical care of study subjects will be the same as for non-participant oocyte donors. Participants in all three study arms will undergo standard ovarian stimulation protocol with gonadotropins, standard individualized adjustment of medication dose, standard criteria for administration of the ovulation trigger dose, and standard egg retrieval procedure.
The recipient population will be recruited from women, age 18 to 55, who present to our center wishing to become pregnant using donor oocytes. All prospective participants who meet the Center for Reproductive Medicine (CRM) criteria be recipients of donated eggs will be eligible to participate, should they wish to do so.
If a prospective recipient consents to participate in the study, then she would be matched with either a donor who is not participating in the study (and is receiving one of our standard triggers for ovulation) or a donor who is participating in the study and whose medication to trigger ovulation has been randomized into one of three groups: standard dose hCG, Leuprolide acetate, or a combination of low dose hCG and Leuprolide acetate.
A recipient who chooses to participate in the study will have no additional tests or procedures over the ones that she would normally do in order to receive donated eggs.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01443546
|Contact: Ina Cholst, M.D.||firstname.lastname@example.org|
|Contact: Rodriq Stubbs, N.P.||email@example.com|
|United States, New York|
|Weill Cornell Medical College- Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine||Recruiting|
|New York, New York, United States, 10021|
|Contact: Rodriq Stubbs, NP 646-962-3276 firstname.lastname@example.org|
|Principal Investigator: Ina Cholst, M.D.|